Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI105917

Catabolism of human γG-immunoglobulins of different heavy chain subclasses: I. Catabolism of γG-myeloma proteins in man

Hans L. Spiegelberg, Ben G. Fishkin, and Howard M. Grey

Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, California 92037

Laboratory Service, Wadsworth General Hospital, Veterans Administration Center, Los Angeles, California 90073

Department of Pathology, University of California School of Medicine, Los Angeles, California 90024

Find articles by Spiegelberg, H. in: JCI | PubMed | Google Scholar

Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, California 92037

Laboratory Service, Wadsworth General Hospital, Veterans Administration Center, Los Angeles, California 90073

Department of Pathology, University of California School of Medicine, Los Angeles, California 90024

Find articles by Fishkin, B. in: JCI | PubMed | Google Scholar

Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, California 92037

Laboratory Service, Wadsworth General Hospital, Veterans Administration Center, Los Angeles, California 90073

Department of Pathology, University of California School of Medicine, Los Angeles, California 90024

Find articles by Grey, H. in: JCI | PubMed | Google Scholar

Published October 1, 1968 - More info

Published in Volume 47, Issue 10 on October 1, 1968
J Clin Invest. 1968;47(10):2323–2330. https://doi.org/10.1172/JCI105917.
© 1968 The American Society for Clinical Investigation
Published October 1, 1968 - Version history
View PDF
Abstract

The rates of catabolism of human γG-immunoglobulins of subclasses γG1, γG2, γG3, and γG4 were studied by determining the rates of elimination from the circulation of pairs of 131I-and 125I-labeled γG-myeloma proteins in 57 patients suffering from cancer other than multiple myeloma. On the average, γG1-, γG2-, and γG4-myeloma proteins were catabolized at a rate similar to that of normal γG-immunoglobulin, whereas γG3-myeloma proteins were catabolized more rapidly than normal γG-immunoglobulin. The average half-lives for the myeloma proteins were 12.3 days for normal γG, 11.6 days for γG1, 12.4 days for γG2, 8.2 days for γG3, and 11.3 days for γG4. However, significant differences in catabolic rates were observed when individual myeloma proteins of a single subclass were compared. These individual variations were present within all four heavy chain subclasses. The extent of differences ranged from 10 to 47%. The catabolic rate of normal γG was in an intermediate range when compared with myeloma proteins of relatively long and short half-lives. The rate of catabolism of an individual myeloma protein did not correlate with its light chain type, Gm factor, carbohydrate content, or electrophoretic mobility. These findings indicate that the structure(s) related to the catabolism of γG-immunoglobulins are complex and differ from one immunoglobulin molecule to another.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2323
page 2323
icon of scanned page 2324
page 2324
icon of scanned page 2325
page 2325
icon of scanned page 2326
page 2326
icon of scanned page 2327
page 2327
icon of scanned page 2328
page 2328
icon of scanned page 2329
page 2329
icon of scanned page 2330
page 2330
Version history
  • Version 1 (October 1, 1968): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts